

## AGENDA

### FRIDAY, OCTOBER 10, 2025

7:00 AM – 8:00 AM	<b>Registration, Breakfast, and Exhibits</b>
8:00 AM – 9:05 AM	<b>Optimizing Patient Care Coordination Between Academic and Community Settings</b>
9:10 AM – 10:10 AM	<b>Deploying Novel Therapies for Acute Lymphoblastic Leukemia</b>
10:10 AM – 10:30 AM	<b>Break and Exhibits</b>
10:30 AM – 11:00 AM	<b>Role of Allogeneic Transplants in Acute Lymphoblastic Leukemia</b>
11:05 AM – 11:35 AM	<b>Integrating New Therapies for the Treatment of Chronic Phase Chronic Myeloid Leukemia</b>
11:40 AM – 12:10 PM	<b>Incorporating TKIs in the Treatment of Myelofibrosis</b>
12:10 PM – 1:25 PM	<b>Lunch and Exhibits</b>
12:15 PM – 12:45 PM	<b>Non-CE Product Theater*: Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma</b> <i>Presented by Genentech</i>
12:50 PM – 1:20 PM	<b>Non-CE Product Theater*: Rethinking BTK Inhibition in Previously Treated CLL/SLL and MCL</b> <i>Presented by Eli Lilly and Company</i>
1:25 PM – 1:55 PM	<b>Emerging Treatment Strategies for High-Risk Myelodysplastic Syndromes</b>
2:00 PM – 3:00 PM	<b>Evolving Treatment Strategies for Acute Myeloid Leukemia</b>
3:00 PM – 3:20 PM	<b>Break and Exhibits</b>
3:20 PM – 4:50 PM	<b>Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma</b>
4:55 PM – 6:00 PM	<b>Monitoring Toxicities in the Ambulatory Setting</b>
6:00 PM – 7:30 PM	<b>Welcome Reception (In-Person Only Event)</b>

### SATURDAY, OCTOBER 11, 2025

7:00 AM – 8:00 AM	<b>Registration, Breakfast, and Exhibits</b>
7:20 AM – 7:50 AM	<b>Non-CE Product Theater*: Reducing Access Barriers: New FDA Label Updates on Cell Therapy Post-treatment Monitoring Requirements</b> <i>Presented by Bristol Myers Squibb</i>
8:00 AM – 9:05 AM	<b>The Role of Minimal Residual Disease in Hematologic Malignancies</b>
9:10 AM – 9:55 AM	<b>Emerging Treatment Options for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</b>
9:55 AM – 10:15 AM	<b>Break and Exhibits</b>
10:15 AM – 11:00 AM	<b>Evolving Treatment Options for Relapsed/Refractory Follicular Lymphoma</b>
11:05 AM – 11:50 AM	<b>Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma</b>
11:55 AM – 12:45 PM	<b>Novel Treatment Options for Hodgkin Lymphoma</b>

### ON-DEMAND SESSIONS

**Diagnosis and Management of Secondary Hemophagocytic Lymphohistiocytosis**  
**Optimizing Cytoreductive Therapy for Polycythemia Vera**  
**Comprehensive Care for Adult Survivors of Hematologic Malignancies**  
**Fertility Preservation in Hematologic Malignancies: Navigating Complex Choices**  
**Evolving Treatment Options for Low-Risk Myelodysplastic Syndromes**  
**Management of High-Risk Acute Promyelocytic Leukemia in the Community Setting**

*Agenda is subject to change. All times are listed as Pacific Daylight Time (UTC/GMT -7).*

*\*Not CE-certified. The information and views expressed in these presentations are solely that of the presenters and do not necessarily reflect the position and policies of NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.*

[NCCN.org/hem-congress](https://www.nccn.org/hem-congress)